Summary

Persistence Market Research (PMR) has recently published a comprehensive report on the global Immune Checkpoint Inhibitors (ICIs) Market, projecting substantial growth over the forecast period from 2024 to 2034. The market is estimated to achieve a valuation of US$107 billion by the year 2034, driven by a robust CAGR of 15%. This growth trajectory is fueled by several key factors, including the rising prevalence of cancer, advancements in immunotherapy, and the expanding adoption of immune checkpoint inhibitors across various cancer types.

Key Insights:

• Immune Checkpoint Inhibitors Market Size (2034F): US$107 Billion
• Global Market Growth Rate (CAGR 2024 to 2034): 15%
• North America Market Share: 65%

Immune Checkpoint Inhibitors Market - Report Scope:

The global Immune Checkpoint Inhibitors Market is on track to reach an impressive valuation of US$107 billion by 2034, driven by a robust CAGR of 15% over the forecast period of 2024 to 2034. This market includes a range of therapies designed to boost the body's immune response against tumor cells, making them crucial in the fight against various cancers. These inhibitors are widely used in hospitals, specialty clinics, and research institutions across the globe, with North America currently leading the market.

Market Growth Drivers:

The global surge in cancer cases, coupled with continuous advancements in immunotherapy, is significantly driving the immune checkpoint inhibitors market. As cancer remains a leading cause of death worldwide, the demand for effective treatments like immune checkpoint inhibitors is increasing. These therapies have revolutionized cancer care by enhancing the immune system's ability to target and eliminate cancer cells, resulting in more durable responses and improved survival rates. Additionally, regulatory approvals for new immune checkpoint inhibitors and expanded indications for existing therapies are crucial in fostering market growth, providing oncologists with a broader range of treatment options and motivating further innovation by pharmaceutical companies.

Market Restraints:

Despite the promising growth trajectory, the immune checkpoint inhibitors market faces several challenges. The advanced nature of these therapies often results in high treatment costs, which can be prohibitive for some patients and healthcare systems. Additionally, severe immune-related side effects experienced by some patients can limit the widespread adoption of certain inhibitors. Access and affordability issues in low-resource settings further hinder market expansion, as limited availability of these advanced therapies in such regions poses a significant barrier to broader market growth.

Market Opportunities:

The immune checkpoint inhibitors market presents significant opportunities for growth. The development of novel inhibitors and combination therapies offers substantial potential for market expansion. Additionally, as healthcare infrastructure improves in emerging markets, the accessibility and utilization of immune checkpoint inhibitors are expected to increase. The expansion of indications through ongoing research and regulatory approvals for new cancer types will further boost market growth, providing companies with opportunities to broaden their product portfolios and address a wider range of patient needs.

Key Questions Answered in the Report:
• What are the primary drivers of the global immune checkpoint inhibitors market?
• Which regions are leading the adoption of immune checkpoint inhibitors, and why?
• How are advancements in immunotherapy shaping the competitive landscape of the market?
• What are the major challenges and restraints faced by the market?
• Who are the key players in the immune checkpoint inhibitors market, and what strategies are they employing to stay competitive?
• What are the emerging trends and future prospects in the global immune checkpoint inhibitors market?

Competitive Intelligence and Business Strategy:

Leading players in the immune checkpoint inhibitors market, such as Merck & Co., Bristol-Myers Squibb, and Roche, are at the forefront of innovation. These companies are heavily investing in research and development to bring cutting-edge therapies to the market. Their strategies include expanding their product portfolios, entering strategic collaborations, and focusing on patient education and access. These efforts are aimed at strengthening their market positions and driving the adoption of immune checkpoint inhibitors across the globe.

Key Companies Profiled:

• Sanofi
• F. Hoffmann-La Roche Ltd.
• Merck & Co.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Regeneron Pharmaceuticals Inc.
• AstraZeneca PLC
• Shanghai Jhunsi Biosciences Ltd
• Immutep Ltd
• BeiGene Ltd
• GlaxoSmithKline PLC

Immune Checkpoint Inhibitors Market Segmentation

By Type

• PD-1
• PD-L1
• CTLA-4

By Application

• Lung Cancer
• Breast Cancer
• Melanoma

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region

• North America
• Latin America
• Europe
• South Asia & Oceania
• East Asia
• The Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Immune Checkpoint Inhibitors Market Snapshot, 2024-2031
1.2. Market Opportunity Assessment, 2024-2031, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global GDP Growth Outlook
2.3.2. Global Consumer Spending Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Product Adoption Analysis
3.2. Regulatory Landscape
3.3. Value Chain Analysis
3.4. Key Deals and Mergers
3.5. PESTLE Analysis
3.6. Porter’s Five Force Analysis
4. Global Immune Checkpoint Inhibitors Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
4.1. Global Immune Checkpoint Inhibitors Market Outlook: Type
4.1.1. Introduction / Key Findings
4.1.2. Historical Market Size (US$ Bn) Analysis, By Type, 2019-2023
4.1.3. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
4.1.3.1. PD-1
4.1.3.2. PD-L1
4.1.3.3. CTLA-4
4.2. Market Attractiveness Analysis: Type
4.3. Global Immune Checkpoint Inhibitors Market Outlook: Application
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019-2023
4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
4.3.3.1. Lung Cancer
4.3.3.2. Breast Cancer
4.3.3.3. Melanoma
4.4. Market Attractiveness Analysis: Application
4.5. Global Immune Checkpoint Inhibitors Market Outlook: Distribution Channel
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2023
4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
4.5.3.1. Hospital Pharmacy
4.5.3.2. Retail Pharmacy
4.5.3.3. Online Pharmacy
4.6. Market Attractiveness Analysis: Distribution Channel
5. Global Immune Checkpoint Inhibitors Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2031
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Immune Checkpoint Inhibitors Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
6.3.1. By Country
6.3.2. By Type
6.3.3. By Application
6.3.4. Distribution Channel
6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
6.4.1. U.S.
6.4.2. Canada
6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
6.5.1. PD-1
6.5.2. PD-L1
6.5.3. CTLA-4
6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
6.6.1. Lung Cancer
6.6.2. Breast Cancer
6.6.3. Melanoma
6.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
6.7.1. Hospital Pharmacy
6.7.2. Retail Pharmacy
6.7.3. Online Pharmacy
6.8. Market Attractiveness Analysis
7. Europe Immune Checkpoint Inhibitors Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
7.3.1. By Country
7.3.2. By Type
7.3.3. By Application
7.3.4. Distribution Channel
7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
7.4.1. Germany
7.4.2. France
7.4.3. U.K.
7.4.4. Italy
7.4.5. Spain
7.4.6. Russia
7.4.7. Turkey
7.4.8. Rest of Europe
7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
7.5.1. PD-1
7.5.2. PD-L1
7.5.3. CTLA-4
7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
7.6.1. Lung Cancer
7.6.2. Breast Cancer
7.6.3. Melanoma
7.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
7.7.1. Hospital Pharmacy
7.7.2. Retail Pharmacy
7.7.3. Online Pharmacy
7.8. Market Attractiveness Analysis
8. East Asia Immune Checkpoint Inhibitors Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
8.3.1. By Country
8.3.2. By Type
8.3.3. By Application
8.3.4. Distribution Channel
8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
8.4.1. China
8.4.2. Japan
8.4.3. South Korea
8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
8.5.1. PD-1
8.5.2. PD-L1
8.5.3. CTLA-4
8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
8.6.1. Lung Cancer
8.6.2. Breast Cancer
8.6.3. Melanoma
8.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
8.7.1. Hospital Pharmacy
8.7.2. Retail Pharmacy
8.7.3. Online Pharmacy
8.8. Market Attractiveness Analysis
9. South Asia & Oceania Immune Checkpoint Inhibitors Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
9.3.1. By Country
9.3.2. By Type
9.3.3. By Application
9.3.4. Distribution Channel
9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
9.4.1. India
9.4.2. Southeast Asia
9.4.3. ANZ
9.4.4. Rest of South Asia & Oceania
9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
9.5.1. PD-1
9.5.2. PD-L1
9.5.3. CTLA-4
9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
9.6.1. Lung Cancer
9.6.2. Breast Cancer
9.6.3. Melanoma
9.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
9.7.1. Hospital Pharmacy
9.7.2. Retail Pharmacy
9.7.3. Online Pharmacy
9.8. Market Attractiveness Analysis
10. Latin America Immune Checkpoint Inhibitors Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
10.3.1. By Country
10.3.2. By Type
10.3.3. By Application
10.3.4. Distribution Channel
10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
10.4.1. Brazil
10.4.2. Mexico
10.4.3. Rest of Latin America
10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
10.5.1. PD-1
10.5.2. PD-L1
10.5.3. CTLA-4
10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
10.6.1. Lung Cancer
10.6.2. Breast Cancer
10.6.3. Melanoma
10.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
10.7.1. Hospital Pharmacy
10.7.2. Retail Pharmacy
10.7.3. Online Pharmacy
10.8. Market Attractiveness Analysis
11. Middle East & Africa Immune Checkpoint Inhibitors Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
11.1. Key Highlights
11.2. Pricing Analysis
11.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
11.3.1. By Country
11.3.2. By Type
11.3.3. By Application
11.3.4. Distribution Channel
11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
11.4.1. GCC Countries
11.4.2. Egypt
11.4.3. South Africa
11.4.4. Northern Africa
11.4.5. Rest of Middle East & Africa
11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Type, 2024-2031
11.5.1. PD-1
11.5.2. PD-L1
11.5.3. CTLA-4
11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2024-2031
11.6.1. Lung Cancer
11.6.2. Breast Cancer
11.6.3. Melanoma
11.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
11.7.1. Hospital Pharmacy
11.7.2. Retail Pharmacy
11.7.3. Online Pharmacy
11.8. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2023
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. Sanofi
12.3.1.1. Overview
12.3.1.2. Segments and Products
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. F. Hoffmann-La Roche Ltd.
12.3.3. Merck & Co.
12.3.4. Bristol-Myers Squibb Company
12.3.5. Eli Lilly and Company
12.3.6. Regeneron Pharmaceuticals Inc.
12.3.7. AstraZeneca PLC
12.3.8. Shanghai Jhunsi Biosciences Ltd
12.3.9. Immutep Ltd
12.3.10. BeiGene Ltd
12.3.11. GlaxoSmithKline PLC
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations